Dynavox Group (DYVOX) Fair Value & Analysis
Healthcare · SE · Market cap 7.0B SEK
Fair value as of: Jul 16, 2026
From 15 valuation models · updated 25 days ago
Fair value updated Jul 16, 2026, revised from kr 32.37 to kr 31.90 (−1.5%) since Jun 24, 2026. Share price +20.1% over the past month.
Below-average quality, and screening another 57% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (kr 40.49). The favourable scenario is already priced in.
- Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
56‑month range kr 17.61 – kr 130.52 · fair‑value band kr 23.43 – kr 40.49 · the kr 73.80 price screens above the kr 31.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Dynavox Group (DYVOX) currently trades at kr 73.80, while our model-based Fair Value estimate is kr 31.90, implying the stock looks roughly 56.8% overvalued today. The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Dynavox Group generated revenue of 2.5B SEK at a net margin of 7.3%. Revenue grew 1.2% year over year. It earns a return on equity of 32.5%. Net debt stands at 909M SEK. Fundamentals as of Jul 16, 2026
Our scenario range runs from kr 23.43 (bear case) to kr 40.49 (bull case); at kr 73.80, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 44% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -57%, DYVOX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (kr 52.50) versus Asset-Based (kr 3.81). Highest evidence: ROIC Compounder (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 49 · Market factors (momentum, volatility) 28
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dynavox Group AB (publ), through its subsidiaries, engages in the development and sale of assistive technology products for customers with communication disabilities.
Full company description
Dynavox Group AB (publ), through its subsidiaries, engages in the development and sale of assistive technology products for customers with communication disabilities. The company offers custom designed augmentative and alternative communication (AAC) solutions that enable people with disabilities, such as cerebral palsy, ALS, autism, and spinal cord injury, to communicate on their own. Its communication solutions include language, software, hardware, funding, support, and training. The company operates in Sweden, Norway, Denmark, Belgium, the United States, Germany, France, China, the United Kingdom, Ireland, Australia, and New Zealand. The company was formerly known as Tobii Dynavox AB (publ) and changed its name to Dynavox Group AB (publ) in July 2024. Dynavox Group AB (publ) was incorporated in 2012 and is headquartered in Stockholm, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Dynavox Group reported revenue of kr 2.5B in FY2025 versus kr 871M in FY2021, a compound +29.7%/yr. Reported net income was kr 166M in FY2025, compounding +53.6%/yr from FY2021.
DYVOX screens 57% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Dynavox Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dynavox Group (DYVOX) overvalued or undervalued?
What is the fair value of DYVOX?
What is the quality score of DYVOX?
What is the revenue of Dynavox Group (DYVOX)?
What is the net profit margin of DYVOX?
Does Dynavox Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Dynavox Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.